US12611406B2 Oxopiperazine Cancer Treatment Patent to Inthera
Summary
The USPTO granted patent US12611406B2 to Inthera Bioscience AG on April 28, 2026, covering oxopiperazine derivatives (Compound 1) and methods of using them to treat cancer. The patent names Ulrich Kessler, Beatrice Dolores Pilger Kessler, and Valentino Cattori as inventors and contains 15 claims. The application was filed on June 18, 2021, under application number 18002169. This grant confers exclusive rights to the patented compound and its therapeutic use in the United States.
“The present disclosure provides a method of treating a cancer comprising administering Compound 1: or a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, to a subject in need thereof at a dosage disclosed herein.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
The USPTO issued patent US12611406B2 to Inthera Bioscience AG on April 28, 2026, covering oxopiperazine derivatives designated as Compound 1 for cancer treatment. The patent includes 15 claims and names Ulrich Kessler, Beatrice Dolores Pilger Kessler, and Valentino Cattori as inventors. The filing date was June 18, 2021, under application number 18002169.
Pharmaceutical companies and biotechnology firms developing cancer therapeutics should review this grant to assess potential freedom-to-operate implications or licensing opportunities related to oxopiperazine-based cancer treatments. Competitors working in this chemical space should evaluate whether their compounds fall within the scope of the granted claims.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Oxopiperazine derivatives for the treatment of cancer
Grant US12611406B2 Kind: B2 Apr 28, 2026
Assignee
Inthera Bioscience AG
Inventors
Ulrich Kessler, Beatrice Dolores Pilger Kessler, Valentino Cattori
Abstract
The present disclosure provides a method of treating a cancer comprising administering Compound 1:
or a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, to a subject in need thereof at a dosage disclosed herein.
CPC Classifications
A61K 31/496 A61K 45/06 A61P 35/00
Filing Date
2021-06-18
Application No.
18002169
Claims
15
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.